Dendritic Cell-Based Vaccines for the Therapy of Experimental Tumors

Abstract

Dendritic cells (DCs) are believed to be the most potent antigen-presenting cells able to link the innate and adaptive immune systems. Many studies have focused on different immunotherapeutic approaches to applying DCs as tools to improve anticancer therapy. Although a number of investigations suggesting the benefit of DC-based vaccination during anticancer therapy have been reported, the general knowledge regarding the ultimate methods of DC-vaccine preparation is still unsatisfactory. In this article, the perspectives of DC-based anti-tumor immunotherapy and optimizing strategies of DC vaccination in humans in light of results obtained in mouse models are discussed.

KEYWORDS::

• dendritic cell
• experimental tumor
• preparation of vaccine

Acknowledgements

The authors are grateful to Joanna Rossowska for her interest in this work and for figure preparation.

Financial & competing interests disclosure

This work was supported by grant no. NN401235334 of the Polish Ministry of Science and Higher Education, grant no. IAA500520807 (GA AS CR), no. 301/09/1024 (GA CR), no. NS/10660-3 (GA MZd CR), and the Joint Project under the Agreement of Scientific Cooperation between PAN and AS CR (2009–2011). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work was supported by grant no. NN401235334 of the Polish Ministry of Science and Higher Education, grant no. IAA500520807 (GA AS CR), no. 301/09/1024 (GA CR), no. NS/10660-3 (GA MZd CR), and the Joint Project under the Agreement of Scientific Cooperation between PAN and AS CR (2009–2011). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.